---
title: "MBX Biosciences, Inc. (MBX) Receives a Buy from Mizuho Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289643997.md"
description: "Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences (MBX) with a $57 price target. The broader market consensus for MBX is Strong Buy, with an average price target of $75.43."
datetime: "2026-06-12T21:35:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289643997.md)
  - [en](https://longbridge.com/en/news/289643997.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289643997.md)
---

# MBX Biosciences, Inc. (MBX) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $57.00.

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Sarepta Therapeutics, and Relmada Therapeutics. According to TipRanks, Ear has an average return of 2.4% and a 41.44% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MBX Biosciences, Inc. with a $75.43 average price target.

### Related Stocks

- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md)

## Related News & Research

- [MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/294163609.md)
- [Meet the Gen Z AI whiz at the center of a hedge fund meltdown](https://longbridge.com/en/news/294425537.md)
- [Pendle: AI Yield Tools connect Claude and ChatGPT to autonomous yield execution - 27 Jul 2026](https://longbridge.com/en/news/293868624.md)
- [Northland Securities Keeps Their Buy Rating on Rezolve AI (RZLV)](https://longbridge.com/en/news/294092952.md)
- [ICON partners with Anthropic to deploy Claude AI across clinical trial operations](https://longbridge.com/en/news/294054355.md)